Claims for Patent: 8,658,673

Summary for Patent: 8,658,673

Title:	BETA2-adrenoreceptor agonists
Abstract:	Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
Inventor(s):	Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin Alec (Horsham, GB), Beattie; David (Horsham, GB)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/858,308
Patent Claims:	1. An inhalable pharmaceutical composition comprising: (A) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one or a salt or solvate thereof in inhalable form; and (B) a pharmaceutically acceptable carrier in inhalable form. 2. An inhalable pharmaceutical composition according to claim 1, that contains a daily dose of (A). 3. An inhalable pharmaceutical composition according to claim 2, in which the daily dose of (A) is from 1 .mu.g to 5000 .mu.g. 4. An inhalable pharmaceutical composition according to claim 3, which is a dry powder formulation. 5. An inhalable pharmaceutical composition according to claim 1, in which (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-- 1H-quinolin-2-one maleate. 6. An inhalable pharmaceutical composition according to claim 5, that contains a daily dose of (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate. 7. An inhalable pharmaceutical composition according to claim 6, in which the daily dose of (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate is from 1 .mu.g to 5000 .mu.g. 8. An inhalable pharmaceutical composition according to claim 7, which is a dry powder formulation. 9. A method of treating a patient with an obstructive or inflammatory airways disease which comprises administering to the patient in need of such treatment an inhalable pharmaceutical composition according to claim 1. 10. A method of treating a patient according to claim 9, in which the obstructive or inflammatory airways disease is chronic obstructive pulmonary or airways disease. 11. A method of treating a patient according to claim 9, wherein a dose from 1 .mu.g to 5000 .mu.g of (A) is administered daily. 12. A method of treating a patient with an obstructive or inflammatory airways disease which comprises administering to the patient in need of such treatment an inhalable pharmaceutical composition according to claim 5. 13. A method of treating a patient according to claim 12, in which the obstructive or inflammatory airways disease is chronic obstructive pulmonary or airways disease. 14. A method of treating a patient according to claim 12, wherein a dose from 1 .mu.g to 5000 .mu.g of (A) is administered daily.